Ustekinumab biosimilars matched the originator in plaque psoriasis

Design

Systematic review and meta-analysis of nine phase 3 head-to-head randomised trials

Population

4,532 adults with moderate-to-severe plaque psoriasis

Primary outcome

Percent change in PASI from baseline at 12 weeks

Effect

Mean difference 0.44 (95% CI −0.99 to 1.88; p=0.54) — no clinically meaningful difference

Nine phase 3 randomised trials (4,532 patients) directly comparing ustekinumab biosimilars with the reference biologic in moderate-to-severe plaque psoriasis were pooled. The primary outcome — percent change in PASI at 12 weeks — showed no meaningful difference between biosimilar and originator.

Across efficacy, quality-of-life and safety outcomes the agents were comparable; the few statistically significant differences at 28 weeks were judged not clinically meaningful. A lower rate of anti-drug antibodies with biosimilars rested on heterogeneous, very low-certainty data and should be read cautiously. All trials were industry-funded with follow-up of a year or less.

The practical implication is about access. Where cost limits biologic use — a live constraint in India — biosimilar ustekinumab offers comparable control at lower price, supporting substitution for suitable patients. It does not argue for switching a stable patient without reason, only that starting on a biosimilar is a sound choice.

• PASI change at 12 weeks did not differ between biosimilar and originator (mean difference 0.44, 95% CI −0.99 to 1.88; p=0.54).
• Efficacy, quality-of-life and safety outcomes were comparable; significant 28-week differences were not clinically meaningful.
• Lower anti-drug-antibody rates with biosimilars came from very low-certainty, heterogeneous data.
• Where cost limits access, starting a suitable psoriasis patient on biosimilar ustekinumab is a reasonable choice.

Why it matters

It reframes the biosimilar question from efficacy — which looks settled — to access and cost.

Don't overread it

All trials were industry-funded with a year or less of follow-up; long-term and switching data remain thin.

The statistics, in plain English

A PASI mean difference of 0.44 with a confidence interval straddling zero (−0.99 to 1.88) means no detectable difference. That a few outcomes reached statistical significance without clinical meaning is a reminder that a small p value is not the same as a difference a patient would notice.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.